Coronado Biosciences Receives Notice of Allowance for First U.S. Patent Covering CNDO-109

Coronado Biosciences, Inc., CNDO today announced the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the foundation U.S. patent application for CNDO-109, licensed by Coronado Biosciences from the University College London Business PLC, for its Natural Killer (NK) cell therapy program. The patent, U.S. Patent Application No. 11/856,466, is entitled, "Method for activating natural killer cells by tumor cell preparation in vitro" and has a current expiration date of July 2027. CNDO-109 is a biologic that activates the immune system's NK cells to seek and destroy cancer cells. Preclinical studies of CNDO-109 have demonstrated activity in multiple myeloma, breast cancer, prostate cancer and ovarian cancer and, based on data obtained from a Phase 1 investigator-sponsored clinical trial in patients with acute myeloid leukemia (AML), the Company believes early efficacy was observed. Coronado currently plans to initiate a Phase 1/2 dose escalation trial in AML patients in the second half of 2012.